The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Artificial intelligence (AI) as a decision support tool for practicing oncologists: Gastrointestinal (GI) cancer cases.
 
Mohammad Jahanzeb
Stock and Other Ownership Interests - PrecisCa
Honoraria - Becton Dickinson
Consulting or Advisory Role - Abbvie; AstraZeneca; Becton Dickinson; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Merck; Novartis; Novocure; Pfizer; Puma Biotechnology; Stemline Therapeutics; Takeda
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb/Celgene; Gilead Sciences; Merck; Regeneron; Stemline Therapeutics; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Becton Dickinson; Gilead Sciences; Merck; Novocure; Regeneron; Stemline Therapeutics; takeda
 
Kayla Haines
Employment - Florida Cancer Specialists and Research Institute; OncAdvisor
Consulting or Advisory Role - Janssen Oncology; Precisca; Takeda
 
Erin Shonkwiler
Consulting or Advisory Role - PrecisCa
Travel, Accommodations, Expenses - Precisca
 
Musa Kiyani
Employment - HCA Healthcare
 
Al Benson III
Consulting or Advisory Role - Abbvie; Amgen; Apexigen; Artemida Pharma; Astellas Amgen BioPharama; Boehringer Ingelheim; Boston Scientific; Bristol-Myers Squibb; Delcath Systems; DRG International; Fortvita (Innovent Biologics); GlaxoSmithKline; Harborside Press; Incyte GI Oncology Pipeline; Janssen Oncology; Jazz Pharmaceuticals; Lewin Group; Merck; Merus; Mirati Therapeutics; Novartis DMC; Onviv (Natera); Pfizer; Quirem Medical; Taiho Pharmaceutical; Takeda (Cadence Communications); Teladoc; The Nucleus Group; Therabionic; White Swan; Xencor
Research Funding - Abbvie (Inst); Abbvie (Inst); AIM ImmunoTech (Inst); American College of Radiology (Inst); Amgen (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eikon Therapeutics (Inst); Fate Therapeutics (Inst); GlaxoSmithKline (Inst); Inocras (Inst); ITM Samsung Bioepsis (Inst); ITM Solucin (Inst); ITM Solucin GmbHm (Inst); Lewin Group (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); RM-110-Elevar Therapeutics, INC (Inst); STP-ST-01 - ST. Pharm Co., LTD (Inst); Summit Therapeutics, INC (Inst); SynCoreBio (Inst); Taiho Pharmaceutical (Inst); Tyme, INC (Inst); WCG Clinical INC (Inst); Xencor (Inst)
 
Scott Celinski
Employment - Texas Oncology/US Oncology
Stock and Other Ownership Interests - Natera
 
Christopher Lieu
Consulting or Advisory Role - Flatiron Health (Inst); Pfizer (Inst)
Research Funding - Genentech (Inst)
 
Zev Wainberg
Consulting or Advisory Role - Alligator Bioscience; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bridgebio; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; EMD Serono; Ipsen; Janssen Oncology; Lilly; Merck; Merck KGaA; Novartis; Pfizer; Phanes Therapeutics; Revolution Medicines; Seagen
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Lilly; Merck